




FIG. 1

2/13

	Subject Characteristics by HBV Status (ITT)			Subject Characteristics by HBV Status (EE)		
	HBV+ (n=12)	Non HBV (n=41)	Overall (n=53)	HBV+ (n=11)	Non HBV (n=30)	Overall (n=41)
Age, mean (range) years	57.5 (42 – 77)	60.8 (25 – 84)	60.0 (25 – 84)	55.7 (42 – 67)	59.1.8 (25 – 77)	58.2 (25 – 77)
Sex, Male (%) : Female (%)	12 (100%) : 0 (%)	31 (76%) : 10 (24%)	43 (81%) : 10 (19%)	11 (100%) : 0 (0%)	24 (80%) : 6 (20%)	35 (85.4%) : 6 (14.6%)
Race:						
Asian	8 (66.7%)	2 (4.9%)	10 (18.9%)	7 (63.6%)	1 (3.3%)	8 (19.5%)
Black	1 (8.3%)	4 (9.8%)	5 (9.4%)	1 (9.1%)	1 (3.3%)	2 (4.9%)
White	1 (8.3%)	30 (73.2%)	31 (58.5%)	1 (9.1%)	23 (76.7%)	24 (58.5%)
Other/Unknown	2 (16.7%)	5 (12.2%)	7 (13.2%)	2 (18.2%)	5 (16.7%)	7 (17.2%)
ECOG PS:						
0	4 (33.3%)	15 (36.6%)	19 (35.6%)	4 (36.4%)	12 (40%)	16 (39%)
1	8 (66.7%)	24 (58.5%)	32 (60.4%)	7 (63.6%)	16 (53.3%)	23 (56.1%)
2	0 (0%)	2 (4.9%)	2 (3.8%)	0 (0%)	2 (6.7%)	2 (4.9%)
Childs–Pugh Score:						
A (5–6)	10 (83.3%)	33 (80.5%)	43 (81.1%)	9 (81.8%)	25 (83.3%)	34 (82.9%)
B (7–9)	1 (8.3%)	3 (7.3%)	4 (7.5%)	1 (9.1%)	2 (6.7%)	3 (7.3%)
Unknown	1 (8.3%)	4 (9.8%)	5 (9.4%)	1 (9.1%)	3 (10%)	3 (7.3%)
Cirrhosis, Yes (%) : No (%)	8 (66.7%) : 4 (33.3%)	26 (63.4%) : 15 (36.6%)	34 (64.2%) : 19 (35.8%)	7 (63.6%) : 4 (36.4%)	20 (66.7%) : 10 (33.3%)	27 (65.9%) : 14 (34.1%)

FIG. 2

3/13

	Subject Characteristics by HBV Status (ITT)			Subject Characteristics by HBV Status (EE)		
	HBV+ (n=12)	Non HBV (n=41)	Overall (n=53)	HBV+ (n=11)	Non HBV (n=30)	Overall (n=41)
HCC Risk Factor:						
HBV	12 (100%)	0 (0%)	12 (22.6%)	11 (100%)	0 (0%)	11 (26.8%)
HCV	0 (0%)	15 (36.6%)	15 (28.3%)	0 (0%)	10 (33.6%)	10 (24.4%)
Alcohol	0 (0%)	3 (7.3%)	3 (5.7%)	0 (0%)	3 (10%)	3 (7.3%)
Other/Unknown	6 (50%)	23 (56.1%)	29 (54.7%)	2 (18.2%)	17 (56.7%)	19 (46.3%)
APF ≥ 15 ng/mL at baseline, Yes (%) : No (%)	9 (75%) : 3 (25%)	27 (65.9%) : 14 (34.1%)	36 (67.9%) : 17 (32.1%)	8 (72.7%) : 3 (27.3%)	21 (70%) : 9 (30%)	29 (70.7%) : 12 (29.3%)
Median CC223 dose (mg/day) (range)	30.0 (22.8 – 45.0)	30.0 (19.1 – 45.0)	30.0 (19.1 – 45.0)	30.0 (22.8 – 42.5)	30.0 (19.1 – 45.0)	30.0 (19.1 – 45.0)
Median treatment duration (days) (range)	112.5 (19.0 – 419.0)	56.0 (1.0 – 393.0)	64.0 (1.0 – 419.0)	113 (48.0 – 419.0)	70.0 (23.0 – 393.0)	105.0 (23.0 – 419.0)
Median number of cycles (range)	4 (1 – 15)	2 (1 – 14)	3 (1 – 15)	4 (4 – 15)	2 (1 – 14)	3 (1 – 15)

FIG. 2 continued




FIG. 3B

FIG. 3A

Subject Disposition by HBV Status – Part B HCC Cohort
Enrolled Population

	HBV+ (N=12) n (%)	HBV– (N=41) n (%)	Overall (N=53) n (%)
Subject Disposition			
Ongoing	2 (16.7)	5 (12.2)	7 (13.2)
Discontinued	10 (83.3)	36 (87.8)	46 (86.8)
Reason for Discontinuation			
Adverse event	3 (25.0)	11 (26.8)	14 (26.4)
Disease progression	7 (58.3)	11 (26.8)	18 (34.0)
Withdrew consent	0	4 (9.8)	4 (7.5)
Death	0	5 (12.2)	5 (9.4)
Lost to follow up	0	2 (4.9)	2 (3.8)
Other	0	3 (7.3)	3 (5.7)

FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B





FIG. 7

Efficacy Results	HBV+	HBV-
Median overall survival (months)	12.07	5.16
Median overall progression free survival (weeks)	16	15.43
Objective Response Rate	25%	0%
Disease Control Rate	91.7%	43.9%
Complete Response	0	0
Partial Response	3	0
Stable disease	8	18
Progressive disease	1	5

FIG. 8






FIG. 10